AU2020343029A1 - Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use - Google Patents

Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use Download PDF

Info

Publication number
AU2020343029A1
AU2020343029A1 AU2020343029A AU2020343029A AU2020343029A1 AU 2020343029 A1 AU2020343029 A1 AU 2020343029A1 AU 2020343029 A AU2020343029 A AU 2020343029A AU 2020343029 A AU2020343029 A AU 2020343029A AU 2020343029 A1 AU2020343029 A1 AU 2020343029A1
Authority
AU
Australia
Prior art keywords
vlc
carbon
pufa
disease
disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020343029A
Other languages
English (en)
Inventor
Nicolas G. Bazan
Ricardo Palacios Pelaez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Louisiana State University
Original Assignee
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Louisiana State University filed Critical Louisiana State University
Publication of AU2020343029A1 publication Critical patent/AU2020343029A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020343029A 2019-09-04 2020-09-04 Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use Abandoned AU2020343029A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962895737P 2019-09-04 2019-09-04
US62/895,737 2019-09-04
US201962923770P 2019-10-21 2019-10-21
US62/923,770 2019-10-21
US201962924359P 2019-10-22 2019-10-22
US62/924,359 2019-10-22
US202062964995P 2020-01-23 2020-01-23
US62/964,995 2020-01-23
PCT/US2020/049541 WO2021046448A1 (en) 2019-09-04 2020-09-04 Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use

Publications (1)

Publication Number Publication Date
AU2020343029A1 true AU2020343029A1 (en) 2022-03-31

Family

ID=74853054

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020343029A Abandoned AU2020343029A1 (en) 2019-09-04 2020-09-04 Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use

Country Status (9)

Country Link
US (1) US20220339134A1 (enExample)
EP (1) EP4025201A4 (enExample)
JP (2) JP2022547080A (enExample)
CN (1) CN114650814A (enExample)
AU (1) AU2020343029A1 (enExample)
BR (1) BR112022003985A2 (enExample)
CA (1) CA3153088A1 (enExample)
MX (1) MX2022002687A (enExample)
WO (1) WO2021046448A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022056311A1 (en) * 2020-09-10 2022-03-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
CN118524834A (zh) * 2021-12-03 2024-08-20 株式会社日水 氧化应激缓和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037180A1 (en) * 2008-10-03 2010-04-08 Glycan Biosciences Pty Ltd Anionic oligosaccharide conjugates
US20130190399A1 (en) * 2009-10-31 2013-07-25 Martek Biosciences Corporation Synthesis and use of omega-3 and omega 6 very long chain polyunsaturated fatty acids (VLC-PUFA)
WO2016130522A1 (en) * 2015-02-09 2016-08-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compounds, compositions, and methods for the treatment of inflammatory, degenerative, and neurodegenerative diseases
US20170014365A1 (en) * 2015-07-14 2017-01-19 The Board Of Regents Of The University Of Oklahoma Compositions Containing Very Long Chain Saturated Fatty Acids and Methods of Use
WO2017077528A2 (en) * 2015-11-02 2017-05-11 Salzman Lovelace Investments, Ltd. Methods and pharmaceutical compositions for treatment of lung inflammation
CA3056882A1 (en) * 2017-03-20 2018-09-27 University Of Southern California Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
US20220226270A1 (en) * 2019-04-04 2022-07-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use

Also Published As

Publication number Publication date
JP2025143368A (ja) 2025-10-01
MX2022002687A (es) 2022-06-16
CN114650814A (zh) 2022-06-21
EP4025201A4 (en) 2023-08-30
JP2022547080A (ja) 2022-11-10
BR112022003985A2 (pt) 2022-05-24
EP4025201A1 (en) 2022-07-13
US20220339134A1 (en) 2022-10-27
CA3153088A1 (en) 2021-03-11
WO2021046448A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
Di Gregorio et al. The epithelial-to-mesenchymal transition as a possible therapeutic target in fibrotic disorders
JP2025143368A (ja) 超長鎖多価不飽和脂肪酸であるエロバノイドヒドロキシル化誘導体、および使用方法
EP3165227A1 (en) Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria
JP6778681B2 (ja) Ｈｍｇｂ１媒介性炎症の治療
JP2019511495A (ja) ＧＳＫ３β阻害薬チデグルシブによるＣＤＫＬ５障害の治療
WO2013070879A1 (en) Methods for treating spinal cord injury with lpa receptor antagonists
Wu et al. Recombinant adiponectin peptide promotes neuronal survival after intracerebral haemorrhage by suppressing mitochondrial and ATF4‐CHOP apoptosis pathways in diabetic mice via Smad3 signalling inhibition
JP7850416B2 (ja) 細胞外小胞に含まれるｅｎａｍｐｔの産生および使用
Wang et al. Gut microbiota-derived indoleacetic acid attenuates neuroinflammation and neurodegeneration in glaucoma through ahr/rage pathway
Zhang et al. Lipin2 ameliorates diabetic encephalopathy via suppressing JNK/ERK-mediated NLRP3 inflammasome overactivation
US20240075004A1 (en) Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
WO2017135753A1 (ko) 혈관내피성장인자를 과발현한 줄기세포를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물
CN110121339A (zh) 含单乙酰基二酰基甘油化合物的用于预防或者治疗肝炎的组合物
US20240091220A1 (en) Methods of modulating neuronal and oligodendrocyte survival
US20240000853A1 (en) Lipocalin-type prostaglandin d2 synthase production promoting agent
Liu et al. The potent analgesia of intrathecal 2R, 6R-HNK via TRPA1 inhibition in LF-PENS-induced chronic primary pain model
Lu et al. The gut microbiota alleviates depression by remodeling gut-brain energy metabolism
US20240041813A1 (en) Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
JP2019530741A (ja) 神経保護及び神経疾患におけるｃｇｒｐ受容体アンタゴニストの使用
US11925642B2 (en) Regulation of eIF4E activity for migraine therapy
JP7315729B2 (ja) ２－ペンチルフランを有効成分として含有する退行性脳疾患の治療用組成物
CN104740633A (zh) Shh信号通路特异性抑制剂的应用
WO2022217035A1 (en) Activators of integrated stress response pathway for protection against ferroptosis
TWI429431B (zh) 自養殖型柔軟指形軟珊瑚分離天然物Ｄｉｈｙｄｒｏｓｉｎｕｌａｒｉｎ方法及其用於治療神經退化性疾病
Li Neuroprotective Effects of Monoterpene Indole Alkaloids from Ervatamia officinalis in Experimental Models of Neuroinflammation

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted